[Other] First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.

nitin.kumar668 Post time Half hour(s) ago | Show all posts |Read mode

This post will be closed automatically in 2026-09-28 15:20

Reward20points

journal：Journal of Clinical Oncology

Authors：Ravit Geva; Mark Voskoboynik; Amy M Beebe; Jennifer Gwo; Konstantin Dobrenkov; Elliot Chartash; Georgina V. Long

Published date：2018-5-20

DOI：10.1200/jco.2018.36.15_suppl.3029

PDF link：http://ascopubs.org/doi/pdfdirec ... 18.36.15_suppl.3029

Article link：https://doi.org/10.1200/jco.2018.36.15_suppl.3029

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

nitin.kumar668 Lv.2

Junior Member

post
reply
points
0

[Other] First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.